TearLab Corporation (TEAR) Expected to Post Earnings of -$0.69 Per Share
Analysts expect that TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) will post ($0.69) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have provided estimates for TearLab Corporation’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.73). TearLab Corporation posted earnings of ($0.70) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 1.4%. The business is expected to issue its next quarterly earnings results on Monday, November 6th.
On average, analysts expect that TearLab Corporation will report full-year earnings of ($2.70) per share for the current fiscal year, with EPS estimates ranging from ($2.76) to ($2.64). For the next fiscal year, analysts forecast that the business will report earnings of ($1.70) per share, with EPS estimates ranging from ($2.04) to ($1.36). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow TearLab Corporation.
TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) last issued its quarterly earnings data on Monday, August 14th. The medical research company reported ($0.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.07. The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $6.86 million. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. TearLab Corporation’s quarterly revenue was up 1.4% compared to the same quarter last year.
Several research firms recently weighed in on TEAR. Zacks Investment Research cut shares of TearLab Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 30th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of TearLab Corporation in a report on Tuesday, August 15th. Five research analysts have rated the stock with a buy rating, TearLab Corporation presently has an average rating of “Buy” and a consensus price target of $4.90.
Shares of TearLab Corporation (NASDAQ:TEAR) traded down 0.70% during mid-day trading on Friday, hitting $1.42. 125,877 shares of the stock were exchanged. The company’s market capitalization is $8.15 million. The firm has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.90. TearLab Corporation has a 12-month low of $1.20 and a 12-month high of $7.50.
ILLEGAL ACTIVITY NOTICE: “TearLab Corporation (TEAR) Expected to Post Earnings of -$0.69 Per Share” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/14/tearlab-corporation-tear-expected-to-post-earnings-of-0-69-per-share.html.
About TearLab Corporation
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.